JP2023510866A5 - - Google Patents
Info
- Publication number
- JP2023510866A5 JP2023510866A5 JP2022542784A JP2022542784A JP2023510866A5 JP 2023510866 A5 JP2023510866 A5 JP 2023510866A5 JP 2022542784 A JP2022542784 A JP 2022542784A JP 2022542784 A JP2022542784 A JP 2022542784A JP 2023510866 A5 JP2023510866 A5 JP 2023510866A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cdr3
- cdr2
- cdr1
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025122880A JP2025163070A (ja) | 2020-01-13 | 2025-07-22 | 抗ｇａｌ３抗体および使用方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960300P | 2020-01-13 | 2020-01-13 | |
| US62/960,300 | 2020-01-13 | ||
| US202063024327P | 2020-05-13 | 2020-05-13 | |
| US63/024,327 | 2020-05-13 | ||
| US202063092069P | 2020-10-15 | 2020-10-15 | |
| US63/092,069 | 2020-10-15 | ||
| US202063122409P | 2020-12-07 | 2020-12-07 | |
| US63/122,409 | 2020-12-07 | ||
| PCT/US2021/013136 WO2021146218A1 (en) | 2020-01-13 | 2021-01-12 | Anti-gal3 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025122880A Division JP2025163070A (ja) | 2020-01-13 | 2025-07-22 | 抗ｇａｌ３抗体および使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023510866A JP2023510866A (ja) | 2023-03-15 |
| JP2023510866A5 true JP2023510866A5 (enExample) | 2024-01-22 |
Family
ID=76864188
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542784A Pending JP2023510866A (ja) | 2020-01-13 | 2021-01-12 | 抗ｇａｌ３抗体および使用方法 |
| JP2025122880A Pending JP2025163070A (ja) | 2020-01-13 | 2025-07-22 | 抗ｇａｌ３抗体および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025122880A Pending JP2025163070A (ja) | 2020-01-13 | 2025-07-22 | 抗ｇａｌ３抗体および使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230036181A1 (enExample) |
| EP (1) | EP4090685A4 (enExample) |
| JP (2) | JP2023510866A (enExample) |
| KR (1) | KR20220129030A (enExample) |
| CN (2) | CN119930824A (enExample) |
| AU (1) | AU2021207461A1 (enExample) |
| BR (1) | BR112022013892A2 (enExample) |
| CA (1) | CA3166552A1 (enExample) |
| IL (1) | IL294486A (enExample) |
| MX (1) | MX2022008450A (enExample) |
| WO (1) | WO2021146218A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) * | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| CN115279789A (zh) * | 2019-12-06 | 2022-11-01 | 真和制药有限公司 | 破坏gal3和胰岛素受体或整联蛋白的相互作用的抗体及其使用方法 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| JP2024526764A (ja) * | 2021-07-13 | 2024-07-19 | トゥルーバインディング，インコーポレイテッド | タンパク質凝集を防止する方法 |
| US20230279120A1 (en) * | 2021-11-09 | 2023-09-07 | Truebinding, Inc. | Methods of treating or inhibiting cardiovascular diseases |
| WO2024073511A2 (en) * | 2022-09-28 | 2024-04-04 | Truebinding, Inc. | Therapies with anti-gal3 antibodies |
| JP2026523670A (ja) * | 2024-03-08 | 2026-07-14 | サンメッド セラピューティック リミテッド | 抗ガレクチン３抗体ならびに癲癇および関連疾患におけるその使用 |
| CN118286392A (zh) * | 2024-03-28 | 2024-07-05 | 广州医科大学附属妇女儿童医疗中心 | 重组Galectin-3在治疗慢性炎性脱髓鞘性多发性神经根神经病中的应用 |
| WO2025240949A1 (en) * | 2024-05-17 | 2025-11-20 | The Administrators Of The Tulane Educational Fund | Compositions and methods for the treatment of idiopathic pulmonary fibrosis |
| WO2025264872A1 (en) * | 2024-06-21 | 2025-12-26 | Truebinding, Inc. | Methods and compositions for treating neurodevelopmental disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101222281B1 (ko) * | 2004-03-29 | 2013-01-28 | 가르파마 컴퍼니 리미티드 | 신규 갈렉틴 9 개변체 단백질 및 그 용도 |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| MX2010005282A (es) * | 2007-11-13 | 2010-08-31 | Teva Pharma | Anticuerpos humanizados contra tl1a. |
| US8349579B2 (en) * | 2007-12-13 | 2013-01-08 | Wayne State University | Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer |
| BRPI0919975A2 (pt) * | 2008-10-29 | 2015-12-15 | Bg Medicine Inc | imunoensaio para galectina-3 |
| CN103443125B (zh) * | 2010-11-30 | 2019-05-03 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
| AU2014370393B2 (en) * | 2013-12-27 | 2018-09-20 | Eliaz Therapeutics, Inc. | Plasmapheresis device |
| WO2016004093A2 (en) * | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN111201030B (zh) * | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| JP7539834B2 (ja) * | 2018-02-01 | 2024-08-26 | メモリアル スローン ケタリング キャンサー センター | ガレクチン－３に対する抗体及びその使用方法 |
| WO2019165421A1 (en) * | 2018-02-26 | 2019-08-29 | Minerva Biotechnologies Corporation | Diagnostic methods using anti-muc1* antibodies |
| KR20210124308A (ko) * | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
-
2021
- 2021-01-12 CN CN202510130333.4A patent/CN119930824A/zh active Pending
- 2021-01-12 AU AU2021207461A patent/AU2021207461A1/en active Pending
- 2021-01-12 CA CA3166552A patent/CA3166552A1/en active Pending
- 2021-01-12 MX MX2022008450A patent/MX2022008450A/es unknown
- 2021-01-12 IL IL294486A patent/IL294486A/en unknown
- 2021-01-12 KR KR1020227028093A patent/KR20220129030A/ko active Pending
- 2021-01-12 JP JP2022542784A patent/JP2023510866A/ja active Pending
- 2021-01-12 CN CN202180022171.2A patent/CN115427449A/zh active Pending
- 2021-01-12 EP EP21741281.6A patent/EP4090685A4/en active Pending
- 2021-01-12 BR BR112022013892A patent/BR112022013892A2/pt unknown
- 2021-01-12 WO PCT/US2021/013136 patent/WO2021146218A1/en not_active Ceased
-
2022
- 2022-07-12 US US17/812,159 patent/US20230036181A1/en not_active Abandoned
-
2025
- 2025-01-10 US US19/017,208 patent/US20250145722A1/en active Pending
- 2025-07-22 JP JP2025122880A patent/JP2025163070A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12384822B2 (en) | TAM receptor-binding fusion molecule having non-inflammatory phagocytosis inducing activity | |
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP7458327B2 (ja) | 血液脳関門移動化合物及びその使用 | |
| CN111356701B (zh) | 抗α-突触核蛋白抗体及其用途 | |
| JP6681433B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| JP2021058189A (ja) | ＦｏｌＲ１及びＣＤ３を標的とする二重特異性抗体 | |
| IL294486A (en) | Antibodies against gal3 and methods of use | |
| JP2020520909A (ja) | 治療抗体の適用関連副反応の低減 | |
| EP4069734A1 (en) | Novel molecules for therapy and diagnosis | |
| JP2023502968A (ja) | アミロイド沈着物を標的化するための修飾免疫グロブリン | |
| CN106661103A (zh) | 改进的Aβ初原纤维结合抗体 | |
| CN110719916B (zh) | 抗-trkb抗体 | |
| JP2018538356A (ja) | 組織修復のための二重特異性治療用タンパク質 | |
| JP7403224B2 (ja) | 改良されたｐ２ｘ７受容体結合剤およびこれを含むポリペプチド | |
| JP2026513097A (ja) | 新規な抗ＮａＰｉ２ｂ抗体およびそれをベースとする抗体－薬物コンジュゲート、治療的方法、ならびにそれらの使用 | |
| EP4118116A1 (en) | Musk agonist antibody | |
| WO2023186078A1 (zh) | 针对c-Met的抗体及其用途 | |
| CN109152833B (zh) | 针对肌腱蛋白的人类抗体和其结合片段 | |
| CN121889428A (zh) | 抗MerTK激动剂抗体、抗MerTK双特异性抗体及其应用 | |
| HK40022840B (en) | ANTIBODIES TO α‐SYNUCLEIN AND USES THEREOF |